Can we identify #SLE patients who cd benefit from earlier bDMARDs? Dr Hassan showed 105/209(50%) pts required bDMARDs/Cyclophosphamide. Time-to-therapy was associated with⬇️C3/C4 and⬆️cSLEDAI-2K. More works needed re: biomarkers & varied population #EULAR2021 #POS0175 @RheumNow https://t.co/gK7Ew3WJUj